We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+23.32%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
-$11.8M
Cap. Flow
+$77.2M
Cap. Flow %
6.76%
Top 10 Hldgs %
64.3%
Holding
85
New
15
Increased
23
Reduced
19
Closed
17
Avg Time Held Equity + Options
1.2 years
Top 10 Avg Time Held Equity + Options
1 year
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
1.2 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$51.9M
2
CTLT icon
CATALENT, INC.
CTLT
+$37.6M
3
SNY icon
Sanofi
SNY
+$26.7M
4
BIIB icon
Biogen
BIIB
+$21.8M
5
GSK icon
GSK
GSK
+$18.4M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$96.3M
2
CYH icon
Community Health Systems
CYH
+$21M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17M
4
LNTH icon
Lantheus
LNTH
+$14.6M
5
ABMD
Abiomed Inc
ABMD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 89.7%
2 Miscellaneous 9.48%
3 Communication Services 0.77%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GSK icon
1
GSK
GSK
$99.2B
$124M 10.84%
3,490,457
+551,387
+19% +$18.4M
2018 Q1
19 quarters
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$121M 10.61%
1,064,446
-205,145
-16% -$17M
2020 Q2
10 quarters
NTRA icon
3
Natera
NTRA
$56.7B
$108M 9.45%
2,685,959
+1,260,357
+88% +$51.9M
2022 Q2
2 quarters
SNY icon
4
Sanofi
SNY
$97.3B
$77.7M 6.8%
1,603,348
+607,313
+61% +$26.7M
2022 Q2
2 quarters
GSK icon
5
CALL
GSK
GSK
$99.2B
$73.6M 6.44%
2,093,700
– –
2020 Q4
8 quarters
UTHR icon
6
United Therapeutics
UTHR
$22.9B
$64.7M 5.67%
232,787
-22,439
-9% -$5.66M
2020 Q2
10 quarters
DHR icon
7
Danaher
DHR
$161B
$43.2M 3.78%
183,380
+28
+0% +$6.49K
2018 Q3
17 quarters
TEVA icon
8
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
$43M 3.76%
4,712,597
+649,662
+16% +$5.67M
2020 Q3
9 quarters
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.15B
$41.2M 3.61%
1,620,713
+409,279
+34% +$9.55M
2022 Q2
2 quarters
BIIB icon
10
Biogen
BIIB
$34.4B
$38M 3.33%
137,348
+77,204
+128% +$21.8M
2021 Q4
4 quarters
CTLT icon
11
DELISTED
CATALENT, INC.
CTLT
$31.1M 2.73%
+691,677
New +$37.6M
2022 Q4
0 quarters
ILMN icon
12
Illumina
ILMN
$39.6B
$28.3M 2.48%
143,989
+33,991
+31% +$7.04M
2022 Q1
3 quarters
CLDX icon
13
Celldex Therapeutics
CLDX
$2.16B
$24.9M 2.18%
558,774
-67,598
-11% -$2.41M
2021 Q4
4 quarters
NVST icon
14
Envista
NVST
$3.68B
$21.6M 1.89%
642,405
+9,404
+1% +$322K
2020 Q4
8 quarters
XBI icon
15
State Street SPDR S&P Biotech ETF
XBI
$9.54B
$17.9M 1.57%
216,087
+116,087
+116% +$9.4M
2022 Q2
2 quarters
CNC icon
16
Centene
CNC
$34.2B
$17.6M 1.54%
214,561
+23,253
+12% +$1.9M
2021 Q1
7 quarters
HLN icon
17
Haleon
HLN
$44.5B
$15.1M 1.32%
+1,881,470
New +$12.8M
2022 Q4
0 quarters
ELV icon
18
Elevance Health
ELV
$92.9B
$14.4M 1.26%
28,042
-4,998
-15% -$2.54M
2020 Q4
8 quarters
ICLR icon
19
Icon
ICLR
$13.1B
$13M 1.13%
66,693
+56,481
+553% +$11.2M
2021 Q3
5 quarters
AVTR icon
20
Avantor
AVTR
$11.1B
$12.7M 1.11%
600,200
+525,748
+706% +$10.9M
2020 Q4
8 quarters
THC icon
21
Tenet Healthcare
THC
$21.5B
$12.4M 1.09%
+254,586
New +$11.8M
2022 Q4
0 quarters
MCRB icon
22
Seres Therapeutics
MCRB
$24.7M
$12.3M 1.08%
110,050
+13,259
+14% +$1.78M
2022 Q3
1 quarter
XENE icon
23
Xenon Pharmaceuticals
XENE
$3.24B
$10.9M 0.95%
275,704
+16,092
+6% +$586K
2021 Q4
4 quarters
HUM icon
24
Humana
HUM
$49.6B
$10.7M 0.94%
20,911
-3,661
-15% -$1.92M
2022 Q2
2 quarters
BCRX icon
25
BioCryst Pharmaceuticals
BCRX
$1.99B
$10.1M 0.89%
+880,487
New +$11M
2022 Q4
0 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Eversept Partners held 85 positions worth $1.14B, down 1% from $1.15B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners deployed $77.2M of net new capital in Q4 2022, opening 15 new positions and adding to 23 existing holdings. Its largest new stake was CATALENT, INC.: 691,677 shares worth $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Community Health Systems, an estimated $21M trimmed.

  • Eversept Partners's largest Q4 2022 buy was CATALENT, INC.: 691,677 shares worth $31.1M.
  • Eversept Partners added most to Natera in Q4 2022, an estimated $51.9M increase.
  • Eversept Partners's biggest Q4 2022 reduction was Community Health Systems, cutting an estimated $21M.
  • Eversept Partners fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $96.3M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.14B portfolio in Q4 2022.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2022.
  • Eversept Partners's portfolio value fell 1% quarter-over-quarter to $1.14B.

Based on Eversept Partners's 13F filing for Q4 2022, filed 14 Feb 2023.